RankAlpha logo
Back to Rankings

SGMT

Sagimet BiosciencesA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The balance sheet is materially stronger after the April financing, and management now says existing cash plus the offering should fund acne programs through 2028 and the planned denifanstat Phase 3 readout; that gives SGMT a cleaner path to a real 2H26 de-risking event [#8-K-2026-05-12].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.9.
What can break
A negative read on the acne pivot or a delay in program timing would hit a concentrated, low-revenue biotech hard.
Momentum
85
Value
41
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $14.00 · Bear $4.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-23 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $26.90
Why
Momentum85 · Δ7d -2.9
Value41 · Δ7d +0.1
Sentiment74 · Δ7d +1.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
85
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.9
Δ21d
-8.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
74
33% active weight
Current posture
7d trendImproving
Δ7d
+1.7
Δ21d
+31.1
Why this grade

Composite grade A. Momentum 85.3 / Value 41.1 / Sentiment 74.4

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$439.92M
Beta
-
Shares Out
32.52M
P/E (TTM) · Derived
-9.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.74
Rev YoY
-100.0%
EPS YoY
+12.6%
Gross Margin
-
Op Margin
-1813.8%
Net Debt
-$151.25M
Current Ratio
13.06
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology